Skip to content

Study · Animal study (in vivo) · siberian hamster · 2004

1 result

Feeding and behavioural effects of central administration of the melanocortin 3/4-R antagonist SHU9119 in obese and lean Siberian hamsters.

Schuhler S, Horan TL, Hastings MH, Mercer JG, Morgan PJ, Ebling FJ

Behavioural brain research1 Jul 2004Cited by 19 (Europe PMC)

PMID15196785 (opens in a new tab)DOI10.1016/s0166-4328(03)00260-2 (opens in a new tab)PepBankPUB-15196785
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In Siberian hamsters, intracerebroventricular MTII decreased food intake for up to 24 h after treatment.

    In plain wordsIn Siberian hamsters, MTII injected into the brain reduced food intake for up to 24 hours.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake
    Study

    Siberian hamstern: not reported in source

    Obese and lean Siberian hamsters
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated · intracerebroventricularAs given in this study (Siberian hamster).

    Source sentences

    Summary
    Intra-cerebroventricular treatment with MTII (a MC3/4-R agonist) significantly decreased food intake for up to 24 h after treatment, and SHU9119 reversed these suppressive effects between 4 and 24 h after treatment, a similar time course to that observed when SHU9119 was administered alone.
    1 context sentence
    Title · context
    Feeding and behavioural effects of central administration of the melanocortin 3/4-R antagonist SHU9119 in obese and lean Siberian hamsters.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.